Ting-Ann Wang

Ting-Ann Wang

Auto-generated profile, based on publicly available information

Ting-Ann Wang

Integrative Medical Data Center, Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2023 in Vaccine
Verified
Journal Article
Open access
WSWei-Ju Su
Wei-Ju Su
KCK. Arnold Chan
K. Arnold Chan
JCJen-Hsiang Chuang
Jen-Hsiang Chuang
TWTing-Ann Wang
Ting-Ann Wang
SCShu-Fong Chen
Shu-Fong Chen
CYChin-Hui Yang
Chin-Hui Yang
The ChAdOx1 nCoV-19 (ChAd), mRNA-1273 (m1273), MVC-COV1901 (MVC), and BNT162b2 (BNT) COVID-19 vaccines received authorization for emergency use in Taiwan beginning in February 2021. We investigated acute reactions to homologous primary COVID-19 vaccination series in adults aged ≥ 18 years. In this prospective observational study based on smartphone data (Taiwan V-Watch), we calculated the frequencies of self-reported local and systemic acute reactions within 7 days of a COVID-19 vaccination, and the health effects up to 3 weeks after each dose. Those who reported adverse reactions after both doses were assessed by the McNemar test. During 22 March 2021-13 December 2021, 77,468 adults were enrolled; 59.0 % were female and 77.8 % were aged 18-49 years. For both doses of all four vaccines, the local and systemic reactions were minor in severity and highest on days 1 and 2 after vaccination, and declined markedly until day 7. For 65,367 participants who provided data after the first and second doses, systemic reactions were more frequent after dose 2 of the BNT and m1273 vaccines (McNemar tests: both p < 0.001), while local reactions were more frequent after dose 2 of the m1273 and MVC vaccines (both p < 0.001), compared with dose 1 of the homologous vaccine. Among the participants aged 18-49 years, the percentage who missed work on the day after vaccination was slightly higher among women (9.3 %) than among men (7.0 %). Acute reactogenicity and impact of work absenteeism for the four COVID vaccines in the V-Watch survey were mild and of short duration.

6 July 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
BKBo-I Kuo
Bo-I Kuo
TWTing-Ann Wang
Ting-Ann Wang
TCTeresa Cheng-Chieh Chu
Teresa Cheng-Chieh Chu
CDChan Ding-Cheng
Chan Ding-Cheng
Yi-Chen LeeYi-Chen Lee
Yi-Chen Lee
YHYi-Ting Hsieh
Yi-Ting Hsieh
Background: Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are 2 of the leading causes of vision loss worldwide. As population aging and diabetes prevalence increase, timely detection of these conditions has become essential. However, limited professionalism and insufficient training in ophthalmic screening among general medicine physicians may lead to delayed diagnosis and treatment. Artificial intelligence (AI)–assisted diagnostic tools may help to improve the screening of DR and AMD in routine clinical practice. Objective: This study aims to evaluate the clinical effectiveness and cost-effectiveness of AI-assisted fundus imaging for DR and AMD screening in adults with diabetes and older adults at risk of macular degeneration. Methods: This multicenter, 2-arm, parallel-group, open-label, individual-level randomized controlled trial and patient recruitment are performed at the settings of Family Medicine and Geriatric and Gerontology Care over 4 medical centers in Taiwan. Eligibility includes (1) diabetic individuals aged ≥20 years for DR screening, and (2) individuals aged ≥50 years for AMD screening. The study protocol has been approved by the ethics committees of all participating hospitals, and all participants will provide written informed consent. Results: The study was funded in September 2024, began on October 2, 2025, and is expected to be completed in December 2027. After the pilot implementation phase without randomization, participants will be randomized 1:1 into two groups: (1) AI-assisted screening, and (2) usual physician-only screening. The primary outcomes will include the detection rates (defined as participants with confirmed DR or AMD among all screened participants) and the positive predictive values (defined as participants with confirmed DR or AMD among those who tested positive). Cost-effectiveness analyses will be performed using data derived from the trial results. Conclusions: This study will provide robust evidence on the effectiveness of AI-assisted ophthalmic screening in improving patient eye health outcomes through timely screening and accurate early detection. This strategy may be cost-effective.

28 January 2026 in JMIR Preprints
Verified
Preprint
Open access
BKBo-I Kuo
Bo-I Kuo
TWTing-Ann Wang
Ting-Ann Wang
TCTeresa Cheng-Chieh Chu
Teresa Cheng-Chieh Chu
CDChan Ding-Cheng
Chan Ding-Cheng
Yi-Chen LeeYi-Chen Lee
Yi-Chen Lee
YHYi-Ting Hsieh
Yi-Ting Hsieh
BACKGROUND Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are two of the leading causes of vision loss worldwide. As population aging and diabetes prevalence increase, timely detection of these conditions has become essential. However, limited professionalism and insufficient training of ophthalmic screening in general medicine physicians may lead to delayed diagnosis and treatment. Artificial intelligence (AI)-assisted diagnostic tools may help to improve the screening of DR and AMD in the routine clinical practice. OBJECTIVE To evaluate the clinical effectiveness and cost-effectiveness of AI-assisted fundus imaging for DR and AMD screening in adults with diabetes and older adults at risk of macular degeneration. METHODS This multicenter, two-arm, parallel-group, open-label, individual-level randomized controlled trial and patient recruitment is performed at the settings of Family Medicine and Geriatric and Gerontology Care over four medical centers in Taiwan. Eligibility includes (1) diabetic individuals aged 20 years or more for DR screening, and (2) individuals aged 50 years or more for AMD screening. The study protocol has been approved by the ethics committees of all participating hospitals, and all participants will provide written informed consent. RESULTS The study was funded in September 2024, began on October 2, 2025, and is expected to be completed in December 2027. After the pilot implementation phase without randomization, participants will be randomized 1:1 into two groups: (1) AI-assisted screening and (2) usual physician-only screening. The primary outcomes included the detection rates (defined as participants with confirmed DR or AMD among all screened participants) and the positive predictive values (defined as participants with confirmed DR or AMD among those who tested positive). Cost-effectiveness analyses will be performed using data derived from the trial results. CONCLUSIONS This study will provide robust evidence on the effectiveness of AI-assisted ophthalmic screening in improving patient eye health outcomes through timely screening and accurate early detection. This strategy may be cost-effective. CLINICALTRIAL ClinicalTrials.gov: NCT07069647

24 February 2025 in JMIR Preprints
Verified
Preprint
Open access
CTChu-Lin Tsai
Chu-Lin Tsai
TCTeresa Cheng-Chieh Chu
Teresa Cheng-Chieh Chu
CWChih-Hung Wang
Chih-Hung Wang
WCWei-Tien Chang
Wei-Tien Chang
MTMin-Shan Tsai
Min-Shan Tsai
CHChien-Hua Huang
Chien-Hua Huang
BACKGROUND Advancements in artificial intelligence (AI) have driven substantial breakthroughs in computer-aided detection (CAD) for chest x-ray (CXR) imaging. The National Taiwan University Hospital research team previously developed an AI-based emergency CXR system (Capstone project), which led to the creation of a CXR module. This CXR module has an established model supported by extensive research and is ready for application in clinical trials without requiring additional model training. This study will use 3 submodules of the system: detection of misplaced endotracheal tubes, detection of misplaced nasogastric tubes, and identification of pneumothorax. OBJECTIVE This study aims to apply a real-time CXR CAD system in emergency and critical care settings to evaluate its clinical and economic benefits without requiring additional CXR examinations or altering standard care and procedures. The study will evaluate the impact of CAD system on mortality reduction, postintubation complications, hospital stay duration, workload, and interpretation time, as wells as conduct a cost-effectiveness comparison with standard care. METHODS This study adopts a pilot trial and cluster randomized controlled trial design, with random assignment conducted at the ward level. In the intervention group, units are granted access to AI diagnostic results, while the control group continues standard care practices. Consent will be obtained from attending physicians, residents, and advanced practice nurses in each participating ward. Once consent is secured, these health care providers in the intervention group will be authorized to use the CAD system. Intervention units will have access to AI-generated interpretations, whereas control units will maintain routine medical procedures without access to the AI diagnostic outputs. RESULTS The study was funded in September 2024. Data collection is expected to last from January 2026 to December 2027. CONCLUSIONS This study anticipates that the real-time CXR CAD system will automate the identification and detection of misplaced endotracheal and nasogastric tubes on CXRs, as well as assist clinicians in diagnosing pneumothorax. By reducing the workload of physicians, the system is expected to shorten the time required to detect tube misplacement and pneumothorax, decrease patient mortality and hospital stays, and ultimately lower health care costs. INTERNATIONAL REGISTERED REPORT PRR1-10.2196/72928